{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/diabetes-type-1/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"3b6f1413-616a-5f8a-bdb2-5039d4c9da3d","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field c5d83ae8-ff30-4d85-84f8-40a4abed7f30 --><h2>Changes</h2><!-- end field c5d83ae8-ff30-4d85-84f8-40a4abed7f30 -->","summary":null,"htmlStringContent":"<!-- begin item 9e3a6258-ff66-49a7-927d-f93710582ca2 --><!-- begin field 3073c4cf-8443-416e-8162-300b382e4444 --><p><strong>November 2020 </strong>— minor update. A target HbA1c level for people with type 1 diabetes and chronic kidney disease has been added in line with the Kidney Disease: Improving Global Outcomes (KDIGO) <em>2020 Clinical practice guideline for diabetes management in chronic kidney disease.</em></p><p><strong>August 2020</strong> — minor update. Broken URL links updated.</p><p><strong>July 2020</strong> — reviewed. A literature search was conducted in April 2020 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. </p><ul><li>In adults, the recommendation on eye screening referral has been reworded to clarify the role of GPs and to add information on when this should happen. This is based on the July 2016 update of the National Institute for Health and Care Excellence (NICE) guideline <em>Type 1 diabetes in adults: diagnosis and management </em>[NICE, 2016].</li><li>In children and young people, the recommendation on diabetic eye screening has been amended to add information on when screening should begin. This is based on the November 2016 update of the NICE guideline <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management  </em>[NICE, 2016].</li></ul><!-- end field 3073c4cf-8443-416e-8162-300b382e4444 --><!-- end item 9e3a6258-ff66-49a7-927d-f93710582ca2 -->","topic":{"id":"e0026a38-6f9d-5508-9a1c-f9cb4d041950","topicId":"83d7e1f3-89ef-4bb8-9e6c-8f19b4d34e87","topicName":"Diabetes - type 1","slug":"diabetes-type-1","lastRevised":"Last revised in November 2020","chapters":[{"id":"d661aaf0-a104-5e58-84d5-4a2a8a0f4f5d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"4c43c028-bb33-5fef-9faa-b1109c46c86c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e0b467f1-8df4-5e16-b575-6586d482ff25","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3b6f1413-616a-5f8a-bdb2-5039d4c9da3d","slug":"changes","fullItemName":"Changes"},{"id":"c85ea3eb-a714-591e-9173-893969e82b38","slug":"update","fullItemName":"Update"}]},{"id":"5c1743f6-3cac-5ff9-adaf-cb4e0825d600","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"87ced251-ae95-56bb-af77-2ff4fed8e622","slug":"goals","fullItemName":"Goals"},{"id":"65dfcd12-0085-5a25-bb44-e3c6fc31638d","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5062125f-ab58-5026-aaff-b6b85d231c1c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a8599fb5-b011-56d3-a366-6cf800a0fefa","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"8c093980-e55d-5ca2-b0b5-b2f4510c1c97","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"9c0a7c64-7734-5a4a-83ed-b90c2c0bbe1c","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d65f3cd5-05c6-5a1e-9944-451040c15857","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"d43fa19c-c0e0-573b-b397-39d8c6688f93","slug":"definition","fullItemName":"Definition"},{"id":"8a652055-2d88-550f-8db1-ae8e33b071bd","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"90b285f5-e373-561a-826a-e61feb7838dd","slug":"incidence-prevalence","fullItemName":"Incidence and prevalence"},{"id":"9cae1d9c-e58a-549e-90b2-2d2cadc11677","slug":"prognosis","fullItemName":"Prognosis"},{"id":"6923a3e8-0ad7-53c5-995c-b35c22158c20","slug":"complications","fullItemName":"Complications"}]},{"id":"a8fd4233-8b09-576a-b7a0-7f8ceeb4bdc8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4f5a4b78-cd62-5755-89da-ec0cde4a8f1b","slug":"diagnosis-adults","fullItemName":"Diagnosis - adults"},{"id":"6f5d18f4-c26e-5580-956a-03c18359bca5","slug":"diagnosis-children-young-people","fullItemName":"Diagnosis - children and young people"},{"id":"325f4df9-1bb2-5a87-a070-e07935161353","slug":"when-to-suspect-diabetic-ketoacidosis","fullItemName":"When to suspect diabetic ketoacidosis"},{"id":"2a892a37-ec75-5c0c-b79d-9b550ba6f44a","slug":"when-to-suspect-hypoglycaemia","fullItemName":"When to suspect hypoglycaemia"}]},{"id":"ef2fcfd0-0be0-5051-a142-f33f073f8866","fullItemName":"Management","slug":"management","subChapters":[{"id":"18ccffe2-a6f3-577e-91e5-cb4155aa3217","slug":"management-adults","fullItemName":"Scenario: Management - adults"},{"id":"e6d0bbff-43a3-5fba-bff0-2be7be288c52","slug":"management-children-young-people","fullItemName":"Scenario: Management - children and young people"}]},{"id":"23697cf0-b89b-5f73-af63-48585cfa9295","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"15bdab2b-50dc-5e17-9f62-653119d307ca","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bc8c7324-ac1b-5655-93c6-4b5346239433","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"1558081d-ff31-5041-982a-0995ddcdac09","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"6ce82109-660d-58c4-8f94-f3daf311c5a8","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"59ae6a38-016e-5016-8cee-931384eb78b4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"03942c19-0b79-5891-a48e-fc314241de96","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1f415e38-eb27-5fde-8084-57d74c402a7c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e0b467f1-8df4-5e16-b575-6586d482ff25","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"72d960c8-cf6e-5bb4-88e0-45834c71e1bf","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field f4dd0c32-f770-476f-a62e-e7cfb9c962c0 --><h3>Previous changes</h3><!-- end field f4dd0c32-f770-476f-a62e-e7cfb9c962c0 -->","summary":null,"htmlStringContent":"<!-- begin item 450a4616-b685-4434-9ca0-b2e200b413da --><!-- begin field 4723cb3b-b05d-422a-84b8-17c0c6259cb7 --><p><strong>November 2016</strong> — minor update.</p><ul><li>The National Institute for Health and Care Excellence (NICE) quality standards for diabetes in children and young people have been added to this topic [NICE, 2016]. </li><li>Additional information regarding referral to the diabetic eye screening programme has been added to reflect the November 2016 update to the NICE guideline. </li><li>A recommendation from a Medicines and Healthcare products Regulatory Agency (MHRA) Drug safety update <em>SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis</em> [MHRA, 2016] has been added to this topic.</li></ul><p><strong>November 2015 to February 2016</strong> — reviewed. A literature search was conducted in November 2015 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The recommendations have been updated in line with recommendations in the National Institute for Health and Care Excellence (NICE) guidelines <em>Type 1 diabetes in adults: diagnosis and management </em>[NICE, 2015] and <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management </em>[NICE, 2015].</p><p><strong>February 2015 </strong>— minor update. Typographical errors corrected in the topic.</p><p><strong>December 2014 </strong>— minor update. The recommendations on lipid modification in people with type 1 diabetes have been updated in line with the revised NICE guideline<em> Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease</em>. Some significant changes to the recommendations have been summarized below. Further changes are detailed in the CKS topics on<em> Lipid modification - CVD prevention</em> and <em>CVD risk assessment and management</em>; where necessary.</p><ul><li><strong>Assessing cardiovascular risk: </strong>a risk assessment tool should <em>not</em> be used to assess cardiovascular disease (CVD) risk in people with type 1 diabetes. The section on assessing cardiovascular risk has therefore been removed from this topic.</li><li><strong>Indication for, and choice of, lipid-modification treatment:</strong><ul><li>For people with type 1 diabetes who do not have established CVD, lipid-modification treatment with atorvastatin 20 mg should be offered if the person is older than 40 years of age, has had diabetes for more than 10 years, has established nephropathy, or has other CVD risk factors (such as obesity and high blood pressure). Lipid-modification treatment should be considered for all other people with type 1 diabetes.</li><li>For people with type 1 diabetes who have established CVD, lipid-modification treatment with atorvastatin 80 mg should be advised for the secondary prevention of CVD. A lower dose should be offered if there are adverse effects, increased risk of adverse effects, or if the person prefers a lower dose.</li></ul></li><li><strong>Informed choice:</strong> the decision to start statin treatment should be made after an informed discussion with the person about the risks and benefits of treatment, taking into account factors such as co-morbidities, potential benefits from lifestyle intervention, the person's preference, and life expectancy.</li></ul><p><strong>December 2013 </strong>— minor update. Text has been removed from the section on antiplatelet treatment and links added to the updated CKS topic on <em>Antiplatelet treatment</em>.</p><p><strong>July 2013 </strong>— minor update. Links to the Driver and Vehicle Licensing Agency (DVLA) website have been updated.</p><p><strong>June 2013 </strong>— minor update. The 2013 QOF options for local implementation have been added to this topic.</p><p><strong>July 2012 </strong>— minor update. The NICE diabetes in adults quality standard has been amended. The goals and outcome measures section of this topic has been updated to reflect this.</p><p><strong>March 2012 </strong>— minor update. The 2012/2013 QOF indicators have been added to this topic. Issued in April 2012.</p><p><strong>February 2012 </strong>— minor update. Issued in April 2012. This topic has been updated to include:</p><ul><li>A section on management of a person with type 1 diabetes during periods of fasting (such as during Ramadan).</li><li>Information from guidelines commissioned by NHS Diabetes on 'Recognition, treatment and prevention of hypoglycaemia in the community'.</li></ul><p><strong>November 2011 </strong>— minor update. Information on fitness to drive from the DVLA's guidance for medical practitioners, <em>At a glance guide to the current medical standards of fitness to drive</em>, has been added to this topic [DVLA, 2011]. Issued in December 2011.</p><p><strong>May 2011 </strong>— minor update. The 2011/2012 QOF indicators have been added to this topic. Issued in June 2011.</p><p><strong>March 2011 </strong>— minor update. The NICE quality standards on the management of diabetes have been added. Issued in June 2011.</p><p><strong>September to December 2010 </strong>— this is a new CKS topic. The evidence base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field 4723cb3b-b05d-422a-84b8-17c0c6259cb7 --><!-- end item 450a4616-b685-4434-9ca0-b2e200b413da -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}